Key result
The modified human ventricular cell model successfully reproduced experimental arrhythmic risk biomarkers and predicted APD90 alternans and conduction block under hyperkalaemic conditions.
A newly developed human ventricular cell model accurately replicates experimental arrhythmic risk biomarkers and predicts conduction block and alternans under hyperkalaemic conditions, providing a framework for studying arrhythmogenic substrates in ischemia.
No takes yet. Share an insight, caveat, or question.
May aid in silico modeling of hyperkalemic arrhythmias in ischemia; leaves open human validation and clinical translation.
In this study, several modifications were introduced to a recently proposed human ventricular action potential (AP) model so as to render it suitable for the study of ventricular arrhythmias. These modifications were driven by new sets of experimental data available from the literature and the analysis of several well-established cellular arrhythmic risk biomarkers, namely AP duration at 90 per cent repolarization (APD(90)), AP triangulation, calcium dynamics, restitution properties, APD(90) adaptation to abrupt heart rate changes, and rate dependence of intracellular sodium and calcium concentrations. The proposed methodology represents a novel framework for the development of cardiac cell models. Five stimulation protocols were applied to the original model and the ventricular AP model developed here to compute the described arrhythmic risk biomarkers. In addition, those models were tested in a one-dimensional fibre in which hyperkalaemia was simulated by increasing the extracellular potassium concentration, [K(+)](o). The effective refractory period (ERP), conduction velocity (CV) and the occurrence of APD alternans were investigated. Results show that modifications improved model behaviour as verified by: (i) AP triangulation well within experimental limits (the difference between APD at 50 and 90 per cent repolarization being 78.1 ms); (ii) APD(90) rate adaptation dynamics characterized by fast and slow time constants within physiological ranges (10.1 and 105.9 s); and (iii) maximum S1S2 restitution slope in accordance with experimental data (S(S1S2)=1.0). In simulated tissues under hyperkalaemic conditions, APD(90) progressively shortened with the degree of hyperkalaemia, whereas ERP increased once a threshold in [K(+)](o) was reached ([K(+)](o)≈6 mM). CV decreased with [K(+)](o), and conduction was blocked for [K(+)](o)>10.4 mM. APD(90) alternans were observed for [K(+)](o)>9.8 mM. Those results adequately reproduce experimental observations. This study demonstrated the value of basing the development of AP models on the computation of arrhythmic risk biomarkers, as opposed to joining together independently derived ion channel descriptions to produce a whole-cell AP model, with the new framework providing a better picture of the model performance under a variety of stimulation conditions. On top of replicating experimental data at single-cell level, the model developed here was able to predict the occurrence of APD(90) alternans and areas of conduction block associated with high [K(+)](o) in tissue, which is of relevance for the investigation of the arrhythmogenic substrate in ischaemic hearts.
Carro et al. (2011) studied Cardiac arrhythmias under hyperkalaemic conditions. Modified human ventricular action potential model vs. Original model was evaluated on Arrhythmic risk biomarkers and behavior under hyperkalaemia (ERP, CV, APD alternans). The modified human ventricular cell model successfully reproduced experimental arrhythmic risk biomarkers and predicted APD90 alternans and conduction block under hyperkalaemic conditions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: